Compare CZFS & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZFS | BDTX |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.0M | 171.9M |
| IPO Year | 1995 | 2020 |
| Metric | CZFS | BDTX |
|---|---|---|
| Price | $80.49 | $1.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | 23.8K | ★ 503.7K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | 30.26 | ★ 130.71 |
| EPS | ★ 4.28 | N/A |
| Revenue | ★ $9,881,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.64 | N/A |
| P/E Ratio | $19.07 | ★ N/A |
| Revenue Growth | ★ 2.82 | N/A |
| 52 Week Low | $52.35 | $1.60 |
| 52 Week High | $84.35 | $4.94 |
| Indicator | CZFS | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.65 | 43.63 |
| Support Level | $78.38 | $1.61 |
| Resistance Level | $83.95 | $2.28 |
| Average True Range (ATR) | 1.84 | 0.09 |
| MACD | -0.40 | -0.03 |
| Stochastic Oscillator | 14.67 | 12.70 |
Citizens Financial Services Inc is a Pennsylvania-chartered bank and trust company. The company through its banking subsidiary provides banking activities and services for individual, business, governmental and institutional customers. Its activities and services principally include checking, savings, and time deposit accounts; residential, commercial and agricultural real estate, commercial and industrial, state and political subdivision and consumer loans; and a variety of other specialized financial services. The Trust and Investment division of the Bank offers a full range of client investment, estate, mineral management, and retirement services.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.